FAS Wealth Partners Inc. Acquires 12,352 Shares of Corcept Therapeutics Incorporated $CORT

FAS Wealth Partners Inc. lifted its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 4.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 322,370 shares of the biotechnology company’s stock after acquiring an additional 12,352 shares during the quarter. FAS Wealth Partners Inc.’s holdings in Corcept Therapeutics were worth $12,995,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its position in Corcept Therapeutics by 111.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 507,967 shares of the biotechnology company’s stock valued at $19,404,000 after acquiring an additional 268,155 shares in the last quarter. Avidity Partners Management LP purchased a new stake in shares of Corcept Therapeutics during the 4th quarter worth $766,000. Norges Bank bought a new stake in Corcept Therapeutics during the fourth quarter valued at about $24,213,000. Geode Capital Management LLC grew its stake in Corcept Therapeutics by 38.0% in the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock valued at $92,892,000 after purchasing an additional 734,646 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in Corcept Therapeutics in the fourth quarter worth about $2,021,000. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept’s latest quarterly results exceeded expectations, with earnings of $0.36 per share versus the $0.02 consensus estimate and revenue of $256.15 million versus $221.15 million expected. Revenue increased 31.7% year over year, helping drive the stock to a new 12-month high. Corcept Therapeutics Reaches New 12-Month High After Better-Than-Expected Earnings
• Positive Sentiment: Piper Sandler assigned Corcept an “Overweight” rating, signaling confidence in the company’s growth outlook. Corcept Therapeutics Earns Overweight Rating from Piper Sandler
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $165 price target. The firm raised its FY2026 EPS forecast to $2.15 from $0.80 and increased its Q3 2026 estimate to $0.78 from $0.34, suggesting expectations for significant near-term earnings growth.
• Neutral Sentiment: Brokerages’ average target price is $94.67, materially below the recent $114.49 reference price. This gap indicates analysts have not fully caught up with the rally or see limited upside from current levels. Brokerages Set Corcept Therapeutics Target Price at $94.67
• Negative Sentiment: Despite the bullish rating, HC Wainwright reduced its FY2027 EPS forecast to $3.95 from $5.38 and lowered estimates for Q1–Q4 2027. These revisions raise concerns about the pace of longer-term earnings growth, particularly with CORT trading at a very high valuation.

Wall Street Analyst Weigh In

Several analysts have commented on CORT shares. Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler reissued an “overweight” rating and set a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research report on Thursday. Finally, Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $119.17.

Insider Buying and Selling at Corcept Therapeutics

In other news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $93.13, for a total transaction of $1,862,600.00. Following the sale, the insider directly owned 3,985 shares of the company’s stock, valued at $371,123.05. The trade was a 83.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Atabak Mokari sold 40,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $81.15, for a total value of $3,246,000.00. Following the completion of the transaction, the chief financial officer directly owned 16,130 shares in the company, valued at approximately $1,308,949.50. The trade was a 71.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 300,000 shares of company stock valued at $22,088,050. Company insiders own 20.70% of the company’s stock.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT opened at $114.49 on Monday. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $122.21. The company has a market cap of $12.38 billion, a PE ratio of 272.60 and a beta of 0.45. The business has a 50-day simple moving average of $84.77 and a two-hundred day simple moving average of $56.91.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.02 by $0.34. The firm had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. Corcept Therapeutics’s revenue was up 31.7% on a year-over-year basis. During the same period last year, the firm posted $0.29 EPS. On average, sell-side analysts predict that Corcept Therapeutics Incorporated will post 1.13 earnings per share for the current fiscal year.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.